KR20150023208A

KR20150023208A - Pharmaceutical composition for treating and preventing constipation, food composition

Info

Publication number: KR20150023208A
Application number: KR20140111031A
Authority: KR
Inventors: 김성진
Original assignee: 주식회사 에코덤
Priority date: 2013-08-23
Filing date: 2014-08-25
Publication date: 2015-03-05

Abstract

The present invention relates to a pharmaceutical composition and food composition for preventing and treating constipation using Chamaecyparis obtuse and, more specifically, to a pharmaceutical composition and food composition for effectively preventing and treating constipation using an extract of Chamaecyparis obtuse or a fraction or compound isolated therefrom. The pharmaceutical composition for preventing and treating constipation using Chamaecyparis obtuse of the present invention contains an extract of Chamaecyparis obtuse as an active ingredient. In addition, the extract of Chamaecyparis obtuse is obtained by a maceration extraction method. In addition, the present invention contains, as an active ingredient, a fraction obtained by adding an organic solvent to the extract of Chamaecyparis obtuse. In addition, the present invention contains, as an active ingredient, at least one compound selected from dihydrosesamin, hinokiflavone, savinin, and isocryptomerin, which are isolated from the extract of Chamaecyparis obtuse.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a pharmaceutical composition for preventing and treating constipation,

The present invention relates to a pharmaceutical composition and a food composition for preventing and treating constipation by using a fleece, and more particularly, to a pharmaceutical composition and a food composition effective for prevention and treatment of constipation by using an extract of Fleeceae or fractions and compounds isolated therefrom will be.

Recently, the rapid increase in the standard of living has led to a decrease in the consumption of food containing vegetables or fiber, and the demand for high-calorie foods such as animal foods and instant foods has increased, resulting in social problems such as overeating and nutritional imbalance.

There is an increase in the obesity population and diabetes, atherosclerosis, myocardial infarction, hypertension, hyperlipidemia, metabolic diseases such as hypertension and hyperlipidemia due to overeating and nutritional imbalance. And it is becoming a serious problem for the society which threatens the welfare of the people.

As part of efforts to prevent and treat these metabolic diseases, we are recommending the intake of dietary fiber and low-calorie foods, avoiding the intake of animal fats and proteins, and not toxic like food-extracted dietary fiber, There is a growing interest in functional foods.

The prevalence of constipation is increasing as well as metabolic diseases due to changes in dietary habits. In recent years, the prevalence of constipation in Korea has increased to 16.5% in women and elderly people (Jeon, Dae-won, 2006).

Constipation refers to a condition in which defecation is not normally performed, and refers to a case in which there is a discomfort or a symptom accompanied by a physiological disorder by decreasing the number of stools and the number of stools when the stool is healthy and dry. Usually, if the number of bowel movements is less than twice a week, or if the daily bowel movement is less than 30 g, constipation can be diagnosed. When constipation is present, not only is the abdomen swollen all the time, but also the toxins of the absent side are absorbed into the intestines and absorbed into the blood, thereby promoting aging of the skin, causing headache, acne and skin rash. It can cause hemorrhoids such as escape of the hemorrhoids. In addition, constipation is a cause of diverse and serious secondary diseases such as bad breath, colorectal diseases such as colorectal cancer, arteriosclerosis, hypertension, stroke, immune deficiency and so, active prevention and treatment are needed.

So far, various medicines and functional foods have been sold for the purpose of revitalizing bowel function and constipation, but the effect is temporary and causes various side effects depending on the kind. For example, when a stimulant containing an anthraquinone derivative such as senna or rhubarb is used as a herbal medicine, there are side effects such as abdominal pain and diarrhea, and it has been pointed out that there is a problem in taking or continuously taking during pregnancy. In addition, various functional foods including kelp, yacon, Saururus chinensis, Culchaem tea, Allium tea, aloe, algae, etc. have not been scientifically proved to be effective enough to solve the fundamental problem of constipation improvement. Reliability is inferior.

Various methods have been studied to solve the above problems, and various pharmaceuticals or foods have been developed as a result. For example, in order to solve the problem of constipation and the like, the activity of the intestinal function can be regarded as a top priority.

For example, Korean Patent Publication No. 180452 discloses a health nutritional composition having an effect of improving constipation and alteration, comprising an extract of Aloe veraensens powder and an extract obtained by extracting an effective ingredient of Saururus trifoliatus with alcohol or a powder thereof as a main component, And an extract obtained by extracting an effective ingredient of the extract or a powder thereof. In addition, Korean Patent Laid-Open Publication No. 99-84271 discloses a method for producing a compound of formula (I) from a group consisting of a bamboo shoot, a bamboo leaf, a crystalloid, a lily leaf, a presbyopia, a rhubarb, And Korean Patent Publication No. 149389 discloses a herbal composition composition for treating constipation using dried tangerine peel, ginseng, omija, alpine, licorice, apricot seed, and gugija .

Thus, many studies have been conducted to solve constipation using natural plants.

It is an object of the present invention to provide a pharmaceutical composition and a food composition effective for prevention and treatment of constipation by using the whitening composition, and it is intended to confirm that the whitening extract and the fractions and the compounds isolated therefrom are effective for the prevention and treatment of constipation .

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing and treating constipation, which comprises an albumen extract as an active ingredient.

The white cotton extract is characterized in that the white cotton, which has been dried by applying hot air at 40 DEG C and pulverized to a size of 1 to 2 mm, is extracted by the cold extraction method.

In the cold extraction method, an extraction solvent is added to the whitening, and extraction is performed at 10 to 50 ° C for 3 to 12 hours.

And the extraction solvent is ethanol.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing and treating constipation, which comprises a fraction obtained by fractionating an extract of an opacifying agent with an organic solvent as an active ingredient.

Wherein the fraction is a methylene chloride fraction obtained by fractionating methylene chloride with the organic solvent or an ethyl acetate fraction obtained by fractionating ethyl acetate with the organic solvent.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing and treating constipation, which comprises at least one compound selected from dihydrocisamine, hinokiflavone, sabinine, and isocryptomeline, By weight.

In order to attain the above object, the food composition of the present invention is characterized by containing an albumen extract as an active ingredient.

As described above, the present invention can provide a pharmaceutical composition and a food composition that can prevent, ameliorate, or treat constipation by using the extract of Fagus crenata. In particular, the extract of the cotton wool extracted by the cold extract extraction method is more effective than the extract of the cotton wool extracted by other extraction methods.

In addition, fractions isolated from the cottonseed extract and components such as dihydrosesamin, hinokiflavone, savinin, and isocryptomerin also have the effect of preventing or treating constipation.

FIG. 1 and FIG. 2 are graphs showing the yields of the extracted samples of L1201, L1204, L1205, L1202, L1206 and L1207 and the contents of the constituents,
FIGS. 3 and 4 are graphs showing the yields of L1207 and L1208 extracted samples and the contents of constituents,
FIGS. 5 and 6 are graphs showing the yields of L1211, L1212 and L1207 extracted samples and the contents of constituents,
7 and 8 are graphs showing the yields of L1213 and L1207 extracted samples and the content of constituent components,
9 and 10 are graphs showing the yields of L1214 and L1207 extracted samples and the content of constituents,
11 and 12 are graphs showing the results of fractionation of the methylene chloride fractions,
13 is a schematic diagram schematically illustrating a separation process for obtaining small fractions from a methylene chloride fraction,
14 is a graph showing the results of HPLC performed on the four small fractions (MC.2-1, MC.2-2, MC.2-3, MC.2-4) isolated from MC.2 ,
15 to 17 are graphs showing the results of HPLC performed on the four small fractions (MC.1-1, MC1-2, MC.1-3) isolated from MC.1,
18 is a schematic diagram showing a separation process for obtaining small fractions from the ethyl acetate fraction,
19 is a graph showing the results of performing HPLC on EA.1-10 among the 11 small fractions separated from EA.1,
20 is a graph showing the results of ¹ H-NMR and ¹³ C-NMR analysis of the compound CHAOB 01 finally separated from the methylene chloride fraction,
21 is a graph showing the results of ¹ H-NMR and ¹³ C-NMR analysis of the compound CHAOB 02 finally isolated from the methylene chloride fraction,
22 is a graph showing the results of ¹ H-NMR and ¹³ C-NMR analysis of the compound CHAOB 04 finally separated from the ethyl acetate fraction,
23 is a graph showing the change in electrical activity when treating the callus stromal cells with the extract of the flatulence extract,
FIG. 24 is a graph showing changes in electrical activity when the methylene chloride fraction is treated with karelein stromal cells,
25 is a graph showing the change in electrical activity when the ethacetate fraction was treated with karelein stromal cells,
FIG. 26 is a graph showing the results of measuring the first stool discharge time and variable weight by administering 2.5 mg / kg and 5 mg / kg of the supercritical white-collar extract,
27 is a graph showing the result of measurement of the variable weight by administering the extract of the cold-pressed facial hair,
FIG. 28 is a graph showing the result of measuring the variable weights after the administration of the cold-pressed retinolate extract, the hexane fraction, the methylene chloride fraction, the ethyl acetate fraction and the butanol fraction,
FIG. 29 is a graph showing the results of measurement of variable weight after administration of the cold-pressed facial hair extract and hinoki flavone,
FIG. 30 is a graph showing the results of measuring the total variance after administering each of the cold-pressed monotherapy extract, supercritical granular extract, and the constipation treatment drug prucalopride drug,
FIG. 31 is a graph showing the results of measurement of dry variance after administration of a cold-pressed monofilament extract, a supercritical granular extract, and a prucalopride drug as a constipation treatment drug.

Hereinafter, a pharmaceutical composition and food composition for the prevention and treatment of constipation using the whitening according to a preferred embodiment of the present invention will be described in detail.

The pharmaceutical composition for the prevention and treatment of constipation according to one embodiment of the present invention contains an albumen extract as an active ingredient.

As the pretreatment process to obtain the white flour extract, the white cotton ( chamaecyparis Obtusa leaves, stems, branches and roots can be washed, dried and then pulverized. Drying of the flock is followed by pulverization and extraction to improve the extraction yield. Preferably, the textiles are dried by applying hot air at 40 DEG C and then pulverized to a size of 1 to 2 mm and then extracted.

It is possible to extract the cottonseed extract by various methods. For example, an extracting solvent may be added to at least one of the leaves, stems, branches, and roots of the filamentous fungus, followed by hot water extraction, cold-rolling or warm-up extraction. In this case, the extraction solvent is mixed with the extraction solvent at a weight ratio of 2 to 20 times, and the mixture is extracted at 10 to 150 ° C for 1 to 24 hours. The extraction may be repeated 1 to 5 times, preferably 3 times.

As the extraction solvent, at least one selected from water, a lower alcohol having 1 to 4 carbon atoms, a polyhydric alcohol, or a mixture thereof may be used. As the lower alcohol having 1 to 4 carbon atoms, methanol, ethanol and the like can be used. As the polyhydric alcohol, butylene glycol, propylene glycol, pentylene glycol and the like can be used. Mixtures of water and lower alcohols, mixtures of water and polyhydric alcohols, mixtures of lower alcohols and polyhydric alcohols, or mixtures of water and lower alcohols and polyhydric alcohols can be used as the mixture. In addition, the white flour extract can be obtained by using reflux cooling extraction, ultrasonic extraction, supercritical fluid extraction, or the like.

In the present invention, the preferred method for extracting the white flour extract is a cold extraction method. For example, the extraction solvent is extracted 10 to 50 times by weight of the extraction solvent in at least one of the leaves, stems, branches, and roots after the drying and pulverization, for 3 to 12 hours. A more preferable extraction method is extraction at 20 DEG C for 12 hours. When the cold extraction method is applied, ethanol is preferable as an extraction solvent, particularly preferably 95% ethanol. In the case of cold extraction under the above conditions, the yield of useful index components can be improved.

The extracted monofilament extract may be further subjected to filtration and then concentrated or lyophilized.

The pharmaceutical composition for the prevention and treatment of constipation according to another embodiment of the present invention contains a fraction obtained by fractionating an albumen extract with an organic solvent as an active ingredient. For example, fractions can be obtained by sequential systematic fractionation by adding hexane, methylene chloride, ethyl acetate, and butanol as an organic solvent to the cotton-white extract extracted by the above-described method. Such fractions may be any one of a hexane fraction, a methylene chloride fraction, an ethyl acetate fraction, and a butanol fraction, or a mixture of two or more thereof. Particularly preferred are methylene chloride fractions or ethyl acetate fractions.

The pharmaceutical composition for the prevention and treatment of constipation according to another embodiment of the present invention may further comprise at least one selected from the group consisting of dihydrosesamin, hinokiflavone, savinin, isocryptomerin, And at least one selected compound is contained as an active ingredient.

The fractions may be purified by a variety of purification methods known in the art, such as chromatography, by adding an organic solvent to the leish extract to isolate dihydrocisamine, hinokiflavone, sabinine, and isocryptomelin.

The dihydrocisamine separated from the white flake extract can be represented by the following formula (1).

The hinokiflavone isolated from the white flour extract can be represented by the following formula (2).

And the sabinin isolated from the leish extract can be represented by the following formula (3).

The isocryptomelin isolated from the cottonseed extract can be represented by the following formula (4).

The above-described Flea Bark extract, the fractions isolated therefrom and the compounds of the formulas (1) to (4) can be usefully used for the prevention and treatment of constipation by promoting bowel movement by activating intestinal motility.

The pharmaceutical composition for the prevention and treatment of constipation according to the present invention may contain 0.01 to 99% by weight of at least one of the extracts or the fractions separated therefrom or the compounds of the formulas (1) to (4). Preferably 0.05 to 50% by weight.

The pharmaceutical composition for the prevention and treatment of constipation according to the present invention may be formulated into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, injections, inhalants, suppositories and patches.

The pharmaceutical composition for the prevention and treatment of constipation according to the present invention may further contain suitable pharmaceutically acceptable carriers, excipients and diluents depending on the form of preparation desired.

When prepared for oral administration, for example, binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.); Fillers such as lactose, microcrystalline cellulose, calcium phosphate, and the like; Lubricants such as magnesium stearate, talc, silica, etc., disintegrants such as potato starch, sodium starch glycolate, and the like; Or a pharmaceutically acceptable excipient such as a wetting agent (e.g., sodium lauryl sulfate and the like). Typically, it is in the form of solid dosage forms such as granules, powders, tablets, capsules, etc. Tablets or capsules can be coated by methods known in the art.

Liquid preparations for oral administration may take the form of, for example, solutions, syrups, emulsions, or suspensions, and may be presented as a dry product for constitution with water or other suitable vehicle before use.

Such liquid preparations may optionally contain pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methylcellulose, hydroxy-propylmethylcellulose, hydrogenated edible fats and the like); Emulsifiers (e.g., lecithin, gum arabic, etc.); Non-aqueous vehicles such as almond oil, oily esters, ethyl alcohol, and the like; Preservatives (e.g., methyl or propyl p-hydroxybenzoate, sorbic acid, etc.), and may be prepared by conventional methods. Pharmaceutically acceptable sweeteners preferably include at least one sweetener such as saccharin, sodium saccharin, calcium saccharin, asphaltene, acesulfame potasium, sodium cicamate, alitam, dihydrochalcone sweetener, monelin, Stevioside or sucralose (4,1 ', 6'-trichloro-4,1', 6'-trideoxygalactosucrose), any bulk sweetener such as sorbitol, mannitol, fructose, Such as sucrose, sodium saccharin, calcium saccharin, and any bulk sweetener such as sorbitol, mannitol, fructose, and the like, such as sucrose, glucose, hydrogenated glucose syrup, xylitol, caramel or honey, . &Lt; / RTI >

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The preferred dosage of the pharmaceutical composition for the prevention and treatment of constipation of the present invention varies depending on the condition and the weight of the patient, the degree of the disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. For example, 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. The administration may be carried out once a day or divided into several times.

The pharmaceutical compositions for the prevention and treatment of constipation according to the present invention may be administered to mammals including livestock, human and the like by various routes and may be administered orally, rectally, intravenously, muscularly, subcutaneously, intrauterally, &Lt; / RTI >

Meanwhile, the present invention provides a food composition which contains a composition for preventing and improving constipation, comprising an extract of Fagaceae, a fraction isolated therefrom, or a compound of Chemical Formulas 1 to 4 as an active ingredient. The food composition of the present invention may contain 0.01 to 60% by weight of at least one of the extracts or the fractions separated therefrom or the compounds of the formulas (1) to (4).

The food composition refers to foods that people consume on a daily basis, and is a collective term for people eating and drinking. Therefore, the form of the food composition in the present invention is not particularly limited. It can be manufactured into various forms including beverage, granule, tablet, powder, ring, capsule, wire, noodle, confectionery, meat, fish, herbarium, And is preferably formed into any one form selected from a beverage, a granule, a tablet, a powder, a ring, and a capsule. The food composition of this formulation is easy to carry and is easily ingested at any time and from time to time.

Examples of the food additives include sugars such as monosaccharides, disaccharides, polysaccharides and sugar alcohols and flavorings such as tau martin, stevia extract, saccharin and aspartame, and nutrients, vitamins, edible electrolytes, flavors, , Cheese, chocolate, etc.), pectic acid, alginic acid, organic acid, protective colloid thickening agent, pH adjusting agent, stabilizer, preservative, glycerin, alcohol and carbonating agent.

As an example of the beverage, 0.01 to 60% by weight of at least any one of the fragrance extracts or the fractions separated therefrom or the compounds of the formulas (1) to (4), 5 to 70% by weight of purified water, 0.1 to 5% by weight of taurine, 0.1 to 5% 0.1 to 5% by weight of vitamin A, 0.1 to 5% by weight of vitamin B, and 10 to 20% by weight of carbohydrate. The carbohydrate may be a monosaccharide such as glucose, fructose, etc .; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and xylitol, sorbitol, erythritol, and the like.

In addition, various flavorings such as ordinary beverages may be contained as additional ingredients. Natural flavoring agents such as tau Martin and stevia extract, and synthetic flavoring agents such as saccharin and aspartame may be used as the flavoring agent. Other drinks may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination.

Solid formulations such as granules, tablets, powders, pills, capsules and the like contain 0.01 to 60% by weight of at least one of the extracts or the fractions separated therefrom or the compounds of the formulas (1) to (4) And the like.

EXAMPLES Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following examples.

&Lt; Experimental <

1. Pretreatment of materials

We have purchased and used for the experiments the elucidated trees collected from Jangseong - gun, Jeollanam - do. The leaves were washed with water to remove foreign matter, sealed in a plastic bag and stored in a refrigerator at 4 ℃.

The pretreatment for the extraction was carried out by taking out the untwisted leaves stored in the freezing compartment and dividing them into dry and unbranched. In addition, some of the white leaves stored in the freezer compartment were not dried for comparison with the dried white leaves. The unbleached white leaves were divided into crushed and unbranched.

The drying was carried out by applying hot air at 40 DEG C for about 24 hours, and the pulverization was carried out using a pulverizer to a size of 1 to 2 mm.

2. Extraction

The extraction solvent, which is equivalent to 10 times the weight of the leaf, is extracted from the leaves at 20 ~ 50 ℃ for 3 ~ 12 hours and then filtered. The extract is filtered at 40 ~ 80 ℃ and 70 mbar And concentrated under reduced pressure to extract the white flour extract. Water, 30% ethanol and 95% ethanol were used as extraction solvents.

(1) Comparison of yield and content according to the type of extraction solvent and drying condition

The first extracting sample (L1201), the second extraction sample (L1204), the third extraction sample (L1205), the fourth extraction sample (L1202), the fifth extraction sample (L1206) ) And a sixth extraction sample (L1207). The extraction conditions of each extracted sample are summarized in Table 1 below.

division Dryness Whether or not pulverized Extraction solvent Extraction time Extraction temperature Number of extraction iterations Concentration temperature The first extraction sample × ○ water 12hr 20 ℃ 3rd time 40 ℃ Second extraction
sample × ○ 30% EtOH 12hr 20 ℃ 3rd time 40 ℃ Third extraction
sample × ○ 95% EtOH 12hr 20 ℃ 3rd time 40 ℃ Fourth extraction
sample ○ ○ water 12hr 20 ℃ 3rd time 40 ℃ Fifth extraction
sample ○ ○ 30% EtOH 12hr 20 ℃ 3rd time 40 ℃ Sixth extraction
sample ○ ○ 95% EtOH 12hr 20 ℃ 3rd time 40 ℃

The yield of each extracted sample is shown in FIG. 1, and the content of the components contained in the extracted sample is shown in FIG.

Referring to FIGS. 1 and 2, it can be seen that it is more advantageous to use the dried white yarn regardless of the type of the solvent in terms of the yield. Considering the constituents and the contents, it is preferable to use 95% ethanol as the extraction solvent.

(2) Comparison of yield and content by crushing

The seventh extraction sample (L1208) extracted without crushing the dried soft white leaves was compared with the sixth extraction sample (L1207). The extraction conditions of each extracted sample are summarized in Table 2 below.

division Dryness Whether or not pulverized Extraction solvent Extraction time Extraction temperature Number of extraction iterations Concentration temperature The sixth extraction sample ○ ○ 95% EtOH 12hr 20 ℃ 3rd time 40 ℃ Seventh extraction
sample ○ × 95% EtOH 12hr 20 ℃ 3rd time 40 ℃

The yield of each of the extracted samples is shown in FIG. 3, and the content of the components contained in the extracted sample is shown in FIG.

Referring to FIG. 3 and FIG. 4, it was confirmed that there was a large difference in yield and amount depending on whether or not pulverized. Therefore, it is desirable to grind and extract the whitening materials in the extraction of the white flour extract.

(3) Comparison of yield and content by extraction time

(L1211) and 9th extraction sample (L1212) extracted with different extraction times were compared with the sixth extraction sample (L1207). The extraction conditions of each extracted sample are summarized in Table 3 below.

division Dryness Whether or not pulverized Extraction solvent Extraction time Extraction temperature Number of extraction iterations Concentration temperature The sixth extraction sample ○ ○ 95% EtOH 12hr 20 ℃ 3rd time 40 ℃ Extract 8
sample ○ ○ 95% EtOH 3hr 20 ℃ 3rd time 40 ℃ Ninth extraction
sample ○ ○ 95% EtOH 8hr 20 ℃ 3rd time 40 ℃

The yield of each extracted sample is shown in FIG. 5, and the content of the constituents contained in the extracted sample is shown in FIG.

Referring to FIGS. 5 and 6, when the extraction time was 3 hours and 12 hours, it was found to be advantageous in terms of the water content and the content in comparison with the case of 8 hours.

(4) Comparison of yield and content according to concentration temperature

The 10th extraction sample (L1213) extracted with different concentration temperature was compared with the sixth extraction sample (L1207). The extraction conditions of each extracted sample are summarized in Table 4 below.

division Dryness Whether or not pulverized Extraction solvent Extraction time Extraction temperature Number of extraction iterations Concentration temperature The sixth extraction sample ○ ○ 95% EtOH 12hr 20 ℃ 3rd time 40 ℃ 10th Extraction
sample ○ ○ 95% EtOH 12hr 20 ℃ 3rd time 80 ℃

The yield of each extracted sample is shown in Fig. 7, and the content of constituents contained in the extracted sample is shown in Fig.

Referring to FIGS. 7 and 8, when the concentration temperature was 40 ° C., it was higher than that at 80 ° C., and there was no significant difference in the content.

(5) Comparison of yield and content according to extraction temperature

The 11th extraction sample (L1214) extracted at different extraction temperatures was compared with the sixth extraction sample (L1207). The extraction conditions of each extracted sample are summarized in Table 5 below.

division Dryness Whether or not pulverized Extraction solvent Extraction time Extraction temperature Number of extraction iterations Concentration temperature The sixth extraction sample ○ ○ 95% EtOH 12hr 20 ℃ 3rd time 40 ℃ Eleventh extraction
sample ○ ○ 95% EtOH 12hr 50 ℃ Episode 2 40 ℃

The yield of each extracted sample is shown in FIG. 9, and the content of the constituents contained in the extracted sample is shown in FIG.

9 and 10, there was no significant difference between the extraction temperature of 20 ° C and the yield percentage at 50 ° C, and it was confirmed that the extraction temperature of 20 ° C was somewhat more advantageous in terms of the content.

Through the above extraction experiments, it was confirmed that the extract was obtained by repeatedly extracting with ethanol at 20 to 50 ° C for 1 to 3 times at 20 to 50 ° C and then concentrated under reduced pressure at 40 to 80 ° C by using ethanol as an extraction solvent. Considering both the yield and the content of the components, it is preferable to extract at 20 ° C for 12 hours and then concentrate at 40 ° C.

It was also confirmed that there was a large difference in the yield and the content of the components depending on the presence or absence of the pretreatment process such as drying and pulverization. Therefore, it is considered that it is advantageous to extract the granules by grinding after drying.

1. Fraction

The sixth extraction sample (L1207) extracted under the optimal extraction conditions examined in the above extraction experiment was used as a cold-pressed monofilament extract. In other words, 2 kg of pulverized soft wheat flour was dried, and then 20 kg of 95% ethanol was added thereto. The resulting mixture was extracted three times at 20 ° C. for 12 hours, filtered and concentrated under reduced pressure at 40 ° C. and 70 mbar to obtain 298.3 g of cold-

Next, the cold-pressed monofilament extract was suspended in 1 L of water, and then fractionated systematically with n-hexane, methylene chloride (MC), ethyl acetate (EA) and n-butanol sequentially as an organic solvent to obtain 85.06 g of hexane fraction, , 41.74 g of the ethyl acetate fraction, 81.66 g of the butanol fraction, and 83.34 g of the water fraction.

2. Separation of compounds from methylene chloride fractions

The methylene chloride fraction (19.45 g) was subjected to silica gel column chromatography using a solvent mixture of 100% chloroform (CHCl ₃ ), 100% methanol, chloroform and methanol (100 to 10: 1, by volume) And seven small fractions (MC.1 to MC.7) were obtained. The results of HPLC (high performance lipid chromatography) of the respective small fractions are shown in FIG.

MC.1 (9.71 g) and MC.2 (2.21 g) were fractionated using HP-20 column chromatography. MC.1 was filled in an HP-20 column and eluted with 90% methanol, 95% methanol and 100% methanol to obtain three small fractions (MC.1-1, MC1-2, MC.1-3) , MC.2 was filled into an HP-20 column and eluted with 90% methanol, 95% methanol, 100% methanol, 100% acetone to obtain four small fractions (MC.2-1, MC.2-2, MC .2-3, MC.2-4).

The above separation process for obtaining the small fractions from the methylene chloride fractions is summarized in FIG.

The results of performing HPLC on the four small fractions (MC.2-1, MC.2-2, MC.2-3, MC.2-4) isolated from MC.2 are shown in Fig. MC.2-1 showing strong peaks in the four small fractions was recrystallized and then developed with Acetonitrile / 0.1% Formic acid solvent using Prep-LC to finally obtain compound CHAOB01.

The results of performing HPLC on the four small fractions (MC.1-1, MC1-2, MC.1-3) isolated from MC.1 are shown in Figs. 15 to 17, respectively. Chlorophyll was observed as an impurity in MC1-2 and MC.1-3. MC.1-2 and MC.1-3 showing strong peaks in the three small fractions were recrystallized and then developed with Acetonitrile / 0.1% Formic acid solvent using Prep-LC to obtain compound " CHAOB 02 " .

3. Isolation of the compound from the ethyl acetate fractions

The ethyl acetate fraction (41.74 g) was subjected to silica gel column chromatography using 100% chloroform (CHCl ₃ ), 100% methanol, a mixed solvent of chloroform and methanol (20-1: 1, by volume) Small fractions (EA.1 to EA.7) were obtained.

And 3.7 g of EA.1 among the above-mentioned small fractions was subjected to Sephadex LH-20 column chromatography using methanol as a solvent. For this purpose, a sample solution prepared by dissolving EA.1 in methanol was loaded on top of a column packed with Sephadex LH-20 gel, and then 100% methanol, 90% methanol, 80% methanol, 70% methanol, 60% methanol, 50% 11 small fractions (EA.1-1 to EA.1-11) were obtained by elution in the order of 40% methanol, 30% methanol, 20% methanol, 10% methanol and 100% acetone.

The above separation procedures for obtaining the small fractions from the ethyl acetate fraction are summarized in FIG.

The results of performing HPLC on 125.3 mg of EA.1-10 among the 11 small fractions isolated from EA.1 are shown in Fig. In FIG. 19, the bottom graph is the chromatogram for the white cotton extract. In FIG. 19, EA. 1-10 was recrystallized to separate P-1 and P-2 peaks and then developed with Acetonitrile / 0.1% Formic acid solvent using Prep-LC to obtain compound 'CHAOB 04' 'CHAOB 05' was finally obtained.

4. Analysis of compounds

Molecular structures of the compounds CHAOB 01, CHAOB 02 and CHAOB 05 finally separated from the ethyl acetate fraction were finally confirmed by nuclear magnetic resonance analysis. The ¹ H-NMR and ¹³ C-NMR spectra of the compounds were analyzed using a nuclear magnetic resonance analyzer (AMX-500 Varian Unity plus, Varian Co., USA).

As a result of the analysis, the compound CHAOB 01 is dihydrosesamin represented by the above formula (1) (see FIG. 20), the compound CHAOB 02 is a savinin represented by the above formula (3) 04 is hinokiflavone represented by the above formula (2) (see FIG. 22), and the compound CHAOB 05 is identified as isocryptomerin represented by the above formula (4).

&Lt; RTI ID = 0.0 >

Exercise of the stomach, small intestine, and large intestine is controlled by the exogenous nervous system such as the sympathetic nerves, parasympathetic nerves, and the intrinsic endogenous nervous system, intrinsic endogenous factors, and drugs. In addition, it is known that the autonomic factors of self-regulation, that is, spontaneous activity of smooth muscle and interstitial cells of Cajal (ICC) are involved.

Over the past decade, intensive studies focusing on animal models have revealed that the role of pacemaker in smooth muscle, which is typical of phasic movement in the stomach, small intestine, and large intestine, is derived from carcinoid cells (Huizinga JD, Zarate N, Farrugia G. Physiology, injury, and recovery of interstitial cells of Cajal: basic and clinical science. Gastroenterology 2009 Nov; 137 (5): 1548-56).

The carotid stromal cells are the main cells that control the intestinal and stomach movements. The physiological functions are 1) inducing the electrical phenomenon which causes the spontaneous contraction of the smooth muscle, 2) the progression of the stomach originating from the intestine or the stomach 3) it is involved in the neurotransmission by being located between the terminal and smooth muscle of the nerve and 4) it acts as a modulator of sensory stimuli like stretch receptor .

At present, numerical reduction and morphological changes of carotid stromal cells are observed in intestinal obstruction, achalasia, Hirschsprung's disease, chronic constipation, etc., so that constipation is closely related to carolenic stromal cells (Ohlsson B, Veress B, Lindgren S, Sundkvist G. Enteric ganglioneuritis and abnormal interstitial cells of Cajal: features of inflammatory bowel disease. / Ordog T. Interstitial cells of Cajal in diabetic gastroenteropathy, Neurogastroenterol Motil 2008 Jan; 20 (1): 8-18.).

Therefore, it is aimed to confirm that the elongated extracts and fractions isolated from these extracts can control the intestinal motility by altering electrical activity of carotid intercellular cells.

1. Isolation of carotid stromal cells

Balb / C mice, 10-15 days old, were used as experimental animals without male and female distinction. Anesthetized with ether, then sacrificed by dislocation of the cervical region. And the colon was removed. The contents were removed by incision in a preparation vessel filled with Krebs-Ringer bicarbonate solution at room temperature. After pinning the tissue with pin, the mucosal layer was removed using microscopic scissors under a microscope, and the suture was exposed.

The isolated muscle tissue was treated with 0.1% collagenase (Worthington Biochemical Co., Lakewood, USA), 0.1% bovine serum albumin (Sigma Chemical Co., St. Louis, Mo., USA), trypsin inhibitor , MO, USA) and transferred to Hank's solution containing no Ca ² ⁺ and treated at 37 ° C for 13 minutes. Then, the cells were replaced with Hank's solution containing no Ca ²⁺ and the cells were shaken carefully using a blunt end of a glass pipette.

2. Culture of karell cells

Separated cells were dispensed onto a sterile cover glass coated with murine collagen (2.5 g / ml, Gibco-BRL, Gaithersburg, MD, USA) in 35 mm culture dishes. After 10 minutes, SmGm (smooth muscle growth medium, Clonetics Corp., San Diego, Calif., USA) containing stem cell factor (SCF, 5 ng / ml, Sigma) and 2% antibiotic / antimycotic (Gibco-BRL) And then cultured in a 37 C, 95% O ₂ -5% CO ₂ incubator. On the day following the incubation, 2% antibiotic / antimycotic was excluded from the solution cultured the day before, and the nutrient solution was changed. Experiments were carried out 2 days after culture. Immunofluorescent staining was performed with Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA) using antibody to the kit protein (ACK2, Gibco-BRL). After staining, confocal laser scanning microscopy (FV300, Olympus, Japan) was used.

2. Record of cell membrane voltage and current

The cultured container was transferred to a thermostat provided on an inverted microscope, and the extracellular solution was perfused at a rate of 2 to 3 ml per minute. Membrane currents were recorded in cell-voltage and voltage-clamping modes in current-clamping mode by whole-cell patch clamp. The signal from the patch clamp amplifier (Axopatch 1-D, Axon Instruments, Foster, CA, USA) was observed through a digital oscilloscope and physiological recorder. Axon Instruments) and an IBM-compatible computer. All experiments were carried out at 29 ° C.

3. Results

The results obtained by administering a sample prepared by diluting the cold-pressed monofilament extract (sixth extract sample: L1207) and the methylene chloride fraction and ethyl acetate fraction separated therefrom to water and adjusting the concentration to 100 μg / ml, 25 to 25, respectively.

FIG. 23 is a graph showing the change in electrical activity when the cold-pressed monofilament extract is treated with caraway stromal cells, and FIG. 24 is a graph showing changes in electrical activity when carrageenan stromal cells are treated with methylene chloride fraction. 25 is a graph showing the change in electrical activity when the ethacetate fraction was treated with karele lysate cells.

Experimental results showed that the frequency of pacemaker voltage of carotid artery cells was increased during the administration of the cold - cutaneous whitening extract and the methylene chloride fraction and ethyl acetate fraction. From these results, it can be confirmed that the extracts of Fagaceae, the methylene chloride fractions and the ethyl acetate fractions separated therefrom can change the electrical activity of carotid intercellular cells and control or prevent constipation by controlling intestinal motility.

&Lt; Animal Model Test > The sixth extraction sample (L1207)

For the animal model experiment, the supercritical extract (12th extraction sample) was prepared by supercritical extraction method as described below in addition to the cold-pressed extract (sixth extract sample, L1207) by the cold extraction method.

Twelve extracted samples (hereinafter, supercritical white flour extract) were extracted using a CO ₂ Supercritical Fluid Extraction (0.5 L) equipment (SCFE-0500, Ilshin Autoclave). Specifically, when the temperature of the crystallization tank is stabilized at 40 ° C, the crushed white lentils are dried by using a high-pressure pump, and the anti-solvent (CO ₂ ) is supplied through the upper line to the experimental pressure (300 bar) . During the injection of the gas, the valve was adjusted so that the pressure of the crystallization tank changed linearly with time. After the gas was injected 120 minutes later, the valve under the crystallization tank was opened and slowly exhausted, and pure CO ₂ gas was injected from the top to maintain the pressure inside the crystallization tank constant during the exhaust. Pure CO ₂ gas was injected and then decompression was performed to obtain a supercritical skin extract.

On the other hand, the efficacy of constipation was verified by animal experiments to determine whether the rats were given a barium meal and that they stimulated the discharge of the stool under certain experimental conditions. In the experimental group, constipation was induced by pretreatment with loperamide, followed by 2.5 mg / kg and 5 mg / kg of supercritical white flour extract, respectively. Respectively. The control group (normal) is an untreated group.

Referring to FIG. 26, it was found that the group administered with 5 mg / kg supercritical wash extract at the first passage time was somewhat faster than the control group. And 5 mg / kg of supercritical leukocyte extract were found to have a greater amount of stool than the control group. Therefore, 5mg / kg of supercritical white cotton extract seems to have an effect on constipation.

Next, to examine the effects of the cold-pressed monotherapy extract on constipation, the experimental group induced constipation through loperamide drug pretreatment, followed by 1.25, 2.5, 5, 10, and 20 mg / kg of cold- After the administration of loperamide, the constipation was induced by a positive control. Then, 5 mg / kg of prucalopride drug, which is a constipation treatment drug, was administered, and the variable weight was measured. The results are shown in FIG. The control group (normal) is an untreated group.

Referring to FIG. 27, it was confirmed that the group administered with the cold-pressed herbal extract showed a concentration-dependent efficacy in comparison with the group treated with the prickly opioid drug for constipation treatment. These results also showed that the effect of the cold-pressed monofilament extract was better when compared with the results of supercritical granular extract (see FIG. 26).

In order to investigate the effect of the solvent fraction of the cold-pressed cotton bud extract, constipation was induced by pretreatment with loperamide, followed by the extract of cold-pressed wheat flour (L1207), hexane fraction (Hex f.), Methylene chloride fraction MC f.), Ethylacetate fraction (EA f.) And butanol fraction (BuOH f.) At 5 mg / kg, respectively. The results were shown in FIG. The control group (normal) is an untreated group.

To investigate the effect of the compound hinokiflavone (CHAOB 04), which was finally isolated from the ethyl acetate fraction, the experimental group induced constipation through loperamide drug pretreatment, followed by cold-pressed monocotyledonous extract (L1207), hinokiflavone The results are shown in Fig. 29. The control group (normal) is a non-treatment group, and loperamide alone is a group that induces constipation through pretreatment with roperoimide drug.

28 and 29, it was estimated that the effect of the solvent fraction of the cold-pressed monofilament extract was not clearly distinguished from each other, so that it was expected to be effective as a complex of effective components. However, when 0.125 mg / kg of hinokiflavone was administered The effect of the individual components seems to be high since we can observe that the weight of the sides increases.

To investigate the effects of the extracts of cold-pressed and supercritical pleats on constipation, the experimental group induced constipation by pretreatment with loperamide, followed by supercritical leavening, . The results are shown in FIG. 30 and FIG. 31, respectively. The control group (normal) is a non-treatment group, and loperamide alone is a group that induces constipation through pretreatment with roperoimide drug. Supercritical, supercritical, and ethanol ext, respectively.

Referring to FIGS. 30 and 31, it was found that the group administered with the cold-pressed monofilament extract was more effective than the group administered with the supercritical granular extract or the group administered the prucalopride drug, which is a constipation treatment drug.

As described above, it was confirmed from the above-mentioned experimental results that it is possible to prevent, ameliorate, or treat constipation by the extract of Fagaceae, fractions separated therefrom and various compounds.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be clearly understood that the same is by way of illustration and example only and is not to be taken by way of limitation.

Claims

A pharmaceutical composition for the prevention and treatment of constipation by using a flatulence extract, which comprises an extract of Prunus mume as an active ingredient.

[3] The pharmaceutical composition for preventing and treating constipation according to claim 1, wherein the extract is selected from the group consisting of dried seaweed extracts obtained by drying at 40 [deg.] C and then dried to 1 to 2 mm size.

[3] The pharmaceutical composition for preventing and treating constipation according to claim 2, wherein the extract is extracted at 10 to 50 < [deg.] &Gt; C for 3 to 12 hours.

4. The pharmaceutical composition for preventing and treating constipation according to claim 3, wherein the extraction solvent is ethanol.

A pharmaceutical composition for the prevention and treatment of constipation, which comprises a fraction obtained by adding an organic solvent to an extract of a flatulence extract as an active ingredient.

The pharmaceutical composition according to claim 5, wherein the fraction is a methylene chloride fraction obtained by fractionating methylene chloride with the organic solvent or an ethyl acetate fraction obtained by fractionating ethyl acetate with the organic solvent. Composition.

Characterized in that it contains at least one compound selected from the group consisting of dihydrosesamin, hinokiflavone, savinin and isocryptomerin isolated from the white hen extract as an active ingredient. A pharmaceutical composition for preventing and treating constipation.

A food composition for preventing and treating constipation, which comprises an albumen extract as an active ingredient.